Casdin Partners Master Fund, L Buys 250,000 Shares of Standard BioTools (NASDAQ:LAB) Stock

Standard BioTools Inc. (NASDAQ:LAB) Director Casdin Partners Master Fund, L bought 250,000 shares of the firm’s stock in a transaction on Friday, November 14th. The stock was acquired at an average cost of $1.24 per share, with a total value of $310,000.00. Following the transaction, the director owned 62,750,000 shares in the company, valued at $77,810,000. The trade was a 0.40% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Casdin Partners Master Fund, L also recently made the following trade(s):

• On Monday, November 17th, Casdin Partners Master Fund, L purchased 225,000 shares of Standard BioTools stock. The shares were bought at an average cost of $1.22 per share, for a total transaction of $274,500.00.
• On Thursday, November 13th, Casdin Partners Master Fund, L purchased 450,000 shares of Standard BioTools stock. The stock was bought at an average price of $1.20 per share, with a total value of $540,000.00.
• On Wednesday, November 12th, Casdin Partners Master Fund, L acquired 375,000 shares of Standard BioTools stock. The shares were bought at an average cost of $1.19 per share, with a total value of $446,250.00.
• On Tuesday, November 11th, Casdin Partners Master Fund, L acquired 300,000 shares of Standard BioTools stock. The shares were bought at an average price of $1.20 per share, for a total transaction of $360,000.00.
• On Monday, November 10th, Casdin Partners Master Fund, L bought 275,000 shares of Standard BioTools stock. The stock was bought at an average cost of $1.17 per share, with a total value of $321,750.00.
• On Friday, November 7th, Casdin Partners Master Fund, L bought 225,000 shares of Standard BioTools stock. The shares were bought at an average price of $1.12 per share, with a total value of $252,000.00.
• On Tuesday, September 9th, Casdin Partners Master Fund, L purchased 100,000 shares of Standard BioTools stock. The shares were purchased at an average cost of $1.29 per share, for a total transaction of $129,000.00.
• On Wednesday, September 3rd, Casdin Partners Master Fund, L acquired 250,000 shares of Standard BioTools stock. The stock was purchased at an average cost of $1.27 per share, with a total value of $317,500.00.
• On Tuesday, August 26th, Casdin Partners Master Fund, L acquired 125,000 shares of Standard BioTools stock. The shares were purchased at an average price of $1.26 per share, with a total value of $157,500.00.
• On Monday, August 25th, Casdin Partners Master Fund, L bought 200,000 shares of Standard BioTools stock. The stock was purchased at an average cost of $1.24 per share, for a total transaction of $248,000.00.

Standard BioTools Stock Up 2.5%

Standard BioTools stock opened at $1.24 on Wednesday. Standard BioTools Inc. has a 52-week low of $0.92 and a 52-week high of $2.25. The company has a market cap of $476.86 million, a P/E ratio of -3.88 and a beta of 1.25. The business has a 50-day simple moving average of $1.28 and a two-hundred day simple moving average of $1.23.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Jump Financial LLC purchased a new stake in Standard BioTools in the 1st quarter worth $26,000. IQ EQ FUND MANAGEMENT IRELAND Ltd boosted its stake in shares of Standard BioTools by 115.6% in the first quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 27,119 shares of the company’s stock worth $29,000 after acquiring an additional 14,541 shares during the period. CWM LLC grew its position in shares of Standard BioTools by 101.8% during the first quarter. CWM LLC now owns 29,705 shares of the company’s stock worth $32,000 after purchasing an additional 14,984 shares in the last quarter. Russell Investments Group Ltd. raised its stake in Standard BioTools by 2,989.0% during the 3rd quarter. Russell Investments Group Ltd. now owns 25,021 shares of the company’s stock valued at $33,000 after purchasing an additional 24,211 shares during the period. Finally, Teacher Retirement System of Texas purchased a new position in Standard BioTools in the 1st quarter worth approximately $35,000. Institutional investors own 53.74% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have weighed in on LAB shares. TD Cowen decreased their price target on shares of Standard BioTools from $1.55 to $1.35 and set a “hold” rating on the stock in a research report on Wednesday, November 5th. Cowen lowered Standard BioTools from a “buy” rating to a “hold” rating in a research note on Wednesday, August 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Standard BioTools in a research report on Wednesday, October 8th. Finally, Wall Street Zen lowered Standard BioTools from a “hold” rating to a “strong sell” rating in a report on Saturday, November 8th. Three research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Standard BioTools presently has an average rating of “Reduce” and an average price target of $1.35.

About Standard BioTools

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.